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S260 Poster Session IIObjectives: To evaluate parent and physician perspectives and
patterns of EOL care for children after SCT.
Methods: Retrospective, cross-sectional survey of 141 parents of
children who died of cancer, and primarily received care at one of
two tertiary care pediatric institutions (response rate 64%). Chart re-
view provided additional information. Children for whom SCT was
the last cancer therapy (n5 31) were compared with those for whom
it was not (non-SCT, n5 110).
Results: The SCT group included 22/31 (71%) allogeneic and 9/
31 (29%) autologous SCT. The median (IQR) interval between last
cancer treatment and death was 65 (30-127) days (SCT group) and
25 (8-59) days (non-SCT) (p\0.001). SCT children were more
likely to die from toxicity (p\0.001). SCT parents and physicians
recognized no realistic chance for cure (RCC) later than their non-
SCT peers (Table 1) and were more likely to have a primary goal of
cure/life extension at death (parents p\0.001, physicians
p5 0.02). SCT children were more likely to die in the ICU
(p\0.001), with less opportunity for location of death to be
planned (p\0.001) or hospice to be involved (p\0.001). For
SCT children, resuscitation discussions occurred later (p\0.001)
and resulted in fewer DNR orders (p5 0.028). SCT children
were more likely to suffer highly from their last cancer therapy
(p5 0.034), and experienced more physical and psychological
symptoms (p\0.009 and \0.007, respectively). For the 13 SCT
children whose parent and physician recognized no RCC .7
days before death, intubation was less likely (p5 0.05) and resusci-
tation discussion and LOD planning more likely (both p5 0.02).
SCT parents who recognized no RCC$ 7 days before death along
with the physician, were more likely to prepare for EOL and if
their primary goal was to reduce suffering, to achieve this
(p\0.001).
Conclusion: SCT is associated with significant suffering and less
opportunity to recognize and prepare for EOL. Given the highmor-
bidity and mortality associated with SCT and the shorter time-
frames, children and families undergoing SCT may benefit from
ongoing discussions regarding prognosis, goals and opportunities
to maximize quality of life.
Parent and Physician Understanding of Prognosis: Duration of
recognition of no realistic chance for cure*
SCT (n5 31) non-SCT (n5 110) P†Parents 4 (1-822) 83.5 (29-237) \0.001
Physicians 15.5 (2-30) 84 (29-166) \0.001*Reported as median (inter-quartile range) number of days before death.
†P values correspond to logistic regression models adjusting for time
since death.277
ALTERNATE DAY MICAFUNGIN ANTI-FUNGAL PROPHYLAXIS IN PEDIAT-
RIC PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLAN-
TATION (HSCT): A PHARMACOKINETIC (PK) STUDY
Mehta, P.A.1, Vinks, A.2, Filipovich, A.1, Bleesing, J.1, Jodele, S.1,
Jordon, M.1, Marsh, R.1, Tarin, R.1, Edwards, S.L.1, Fearing, D.1,
Davies, S.M.1 1Cincinnati Children’s Hospital Medical Center, OH;
2Cincinnati Children’s Hospital Medical Center, OH
Disseminated fungal infection is a major cause of morbidity and
mortality in children undergoing HSCT. Prophylaxis with ampho-
tericin B can be limited by it’s renal toxicity. Oral triazoles are lim-
ited by poor absorption, large inter-individual PK variability and
hepatic toxicity, leading to breakthrough infections. Intravenous mi-
cafungin has a distinct advantage due to its better safety profile spe-
cifically in terms of hepatic and renal toxicity, and lack of drug-drug
interactions with common medications used in the HSCT setting.
We hypothesized that higher dose micafungin (3 mg/kg) every other
day will provide drug exposure similar to standard dose (1 mg/kg)
given daily, and improve patient compliance at reduced administra-tion costs. Both animal and adult patient data support the use of this
approach.
Fifteen children (M/F5 11/4, age #10 y; mean 3.9 y, range
0.6-10 y) with various hematological, metabolic and immune de-
ficiency disorders undergoing HSCT received a single dose of
Micafungin (3 mg/kg) intravenously over 1 hour. Dose selection
was based on published PK data in pediatric patients (Seibel et
al. ntimicrob Agents Chemother, 2005), and exploration of differ-
ent dosing regimens using Monte Carlo PK/PD simulation.
Blood samples were drawn around this dose (pre-dose, at the
end of infusion (1 h), and at 1.5, 2, 4, 6, 10, 24, 36 and 48 h
post dose) and PK analysis was conducted using standard non-
compartmental methods. In addition, we evaluated free AUC/
MIC (minimum inhibitory concentration) and Peak/MIC ratios
as target pharmacodynamic indices.
Micafungin at 3 mg/kg dose was well tolerated in all patients.
Measurable plasma concentrations were present in all cases at
48 hours (Table 1). Half-life and clearance observed were compara-
ble to previous pediatric PK data, with clearance being higher than
adults as expected. Volume of distribution was higher in our patients
compared to published pediatric data, likely due to a larger propor-
tion of very young children in our study cohort (\2 yrs, n5 3; 2-5
yrs, n5 9; 5-10 yrs, n5 3).
Our data show measurable plasma levels at 48 hours after
a single 3 mg/kg dose of Micafungin. After correction for pro-
tein binding, concentrations at the end of the dosing interval
during maintenance treatment will remain well above the MIC
of most common fungal pathogens. This finding suggests that
alternate day Micafungin dosing, as described here, may provide
an attractive alternative for antifungal profylaxis in HSCT
patients.
Table 1. Plasma Micafungin Pharmacokinetic Parameters
Standard
Parameters (unit) Mean Deviation (SD) RangeCmax (mg/L) 12.5 2.7 8.25 – 18.69
Cmin (mg/L at 48 hr) 0.8 0.5 0.27 – 1.99
AUC0-24 (hr*mg/L) 128.5 35.9 79.29 – 229.18
AUC0-48 (hr*mg/L) 164.4 50.7 97.46 – 305.16
AUC0-INF (hr*mg/L) 180.8 62.2 104.18 – 352.87
Cl (ml/hr/kg) 17.7 5.8 7.89 – 29.62
T 1⁄2 (h) 13.0 2.1 9.45 – 16.84
Vss (L/kg) 0.3 0.1 0.22 – 0.48Cmax - peak plasma concentration; Cmin - trough plasma concentra-
tion, AUC0-24 area under the plasma concentration-time curve at
24hrs, AUC0-48 area under the plasma concentration-time curve at
48hrs, AUC0-INF area under the plasma concentration-time curve ex-
trapolated to infinity, Cl total body clearance, T 1⁄2 elimination half-life,
Vss volume of distribution.278
DRUG INTERACTION BETWEEN ORAL CALCINEURIN INHIBITORS (TA-
CROLIMUS AND CYCLOSPORINE A) AND ORAL VORICONAZOLE IN THE
RECIPIENTS OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLAN-
TATION
Mori, T., Kato, J., Aisa, Y., Yamane, A., Ono, Y., Okamoto, S. Keio Uni-
versity School of Medicine, Tokyo, Japan
Although drug interaction between calcineurin inhibitors such as
tacrolimus and cyclosporine A (CsA) and voriconazole has long been
recognized, it has not been systemically evaluated. Based on the
limited data, a uniform dose reduction of calcineurin inhibitors on
initiating voriconazole (1/2 for CsA, 1/3 for tacrolimus) is recom-
mended. To date, the administration route (i.v. or oral) on the
drug interaction has not been the main subject of evaluation and dis-
cussion. In the present study, the drug interaction between calci-
neurin inhibitors and voriconazole were evaluated in recipients of
Poster Session II S261allogeneic hematopoietic stem cell transplantation (HSCT), in
whom both agents were orally administered.
Patients and Methods: Eighteen recipients of allogeneic HSCT
who had already been on a steady dose of oral calcineurin inhibitors
(CsA (n5 8) or tacrolimus (n5 10)), and were started on oral
voriconazole (200 mg per body every 12 h) for the treatment or
prophylaxis of fungal infection could be evaluated. The concentra-
tion/dose (C/D; (ng/ml)/(mg/kg)) ratio of calcineurin inhibitors
was calculated 7–10 days after initiating voriconazole when the in-
creased blood levels of calcineurin inhibitors had stabilized. The
plasma level of voriconazole was measure by high-performance
liquid chromatography.
Results: The median C/D ratios of CsA and tacrolimus signif-
icantly increased after initiating voriconazole as compared with
those before initiating voriconazole (P\0.05). Median increases
of C/D ratios after initiating voriconazole were 62.0% with
a range of 0% to 135.8% in CsA-administered patients, and
196.8% with a range of -32.0% to 400.0% in tacrolimus-admin-
istered patients, which tended to be higher in tacrolimus-admin-
istered patients (P5 0.068). The plasma level of voriconazole
measured 7–10 days after initiating voriconazole was
2.266 1.21 mg/ml, and exceeded 2.0 mg/ml in 12 patients
(66.7%). The increase in C/D ratio of CsA and tacrolimus after
initiating voriconazole did not correlate with the plasma level of
voriconazole.
Conclusion:Although calcineurin inhibitors and voriconazole dem-
onstrates a significant interaction when both agents are administered
orally, the magnitude of interaction differs widely among the pa-
tients, and is considered greater with tacrolimus than with CsA.
Since the interindividual difference was not due to the difference
in the bioavailability of oral voriconazole, other mechanisms should
be explored.279
THE UPDATED SCHWARTZ FORMULA AS A SCREENING TEST FOR ABNOR-
MAL KIDNEY FUNCTION PRIOR TO HEMATOPOIETIC STEM CELL TRANS-
PLANTATION
Qayed, M., Thompson, A., Applegate, K., Haight, A., Chiang, K.-Y.,
Horan, J. Emory University and Children’s Healthcare of Atlanta, GA
Assessing renal function is an integral part of evaluating pedi-
atric patients for hematopoietic stem cell transplantation
(HSCT). The most accurate method is DTPA-Tc-99m GFR test-
ing. It, however, is costly and time consuming. The Schwartz
formula, which was recently updated, represents an easy alterna-
tive. To determine the appropriateness of using the updated and
simplified Schwartz formula for pre-transplant screening for ab-
normal kidney function, we compared it to the results obtained
using DTPA-Tc-99m GFR testing, which we routinely perform
as part of our pre-transplant evaluation. We retrospectively re-
viewed the charts of 107 consecutive children over the age of
12 months who underwent HSCT between January 1, 2004
and June 30, 2006, including demographic data, serum creatinine
and DTPA-Tc-99m GFR, height, and primary diagnosis. GFR
was estimated using the updated Schwartz formula (0.413*height
in centimeters/Creatinine). Nuclear medicine measurement of
GFR was carried out using DTPA-Tc-99m per institutional pro-
tocol, and calculated GFR was corrected for body surface area.
The utility of using the calculated GFR as a screening test to
distinguish patients with abnormal GFR (\90 ml/min/1.73 m2)
was tested by Receiver operating characteristic (ROC) curve anal-
ysis. Cut-off points optimizing sensitivity and simultaneously op-
timizing both sensitivity and specificity were determined. There
were 56 males and 51 females. The mean age at transplantation
was 9.1 years (+/-5.8). Eighty five (79.4%) patients had malignan-
cies (table I). The mean estimates of GFR with DTPA-Tc-99m
and the updated formula were 106.62 (S.E, 628.35) and 96.48
(S.E., 626.10), respectively. The area under the curve for calcu-
lated GFR was 0.71 (P5 0.001). The GFR value optimizing both
was 87.4 ml/min/1.73 m2, with sensitivity 67.5% and specificity
64.4% (34% of patients misclassified). At a cut point of109 ml/min/1.73 m2, the sensitivity was 82.5%, however the
specificity was compromised at only 30.2%. The updated
Schwartz formula is a poor screening method for abnormal kid-
ney function in HSCT candidates. Nuclear medicine testing
maybe indicated, especially in heavily pretreated patients.280
PSYCHOSOCIAL FACTORS AS MEASURED BY THE TRANSPLANT EVALUA-
TION RATING SCALE (TERS) PREDICT LENGTH OF HOSPITALIZATION
AND INFECTIOUS COMPLICATIONS FOLLOWING HEMATOPOIETIC
STEM CELL TRANSPLANTATION
Speckhart, D.1, Bashey, A.1,2, Morris, L.E.1,2, Solomon, S.1,2, Berry, T.1,
Holland, H.K.1,2 1Blood and Marrow Transplant Program at Northside
Hospital, Atlanta, GA; 2Blood andMarrow Transplant Group of Georgia,
Atlanta, GA
Although psychological and social factors are recognized as
being important in the evaluation of patients for hematopoietic
stem cell transplantation (HSCT), no standard approach to psy-
chosocial assessment currently exists. In solid organ transplanta-
tion, psychosocial assessments have been integrated into the
selection of appropriate candidates, and certain psychosocial var-
iables, such as active substance abuse, have been shown to neg-
atively impact outcomes in solid organ transplant patients. To
determine whether similar factors impact outcomes in patients
undergoing HSCT, we prospectively conducted psychosocial as-
sessments on 155 consecutive patients undergoing autologous
HSCT primarily initiated in an outpatient setting. The relation-
ship between psychosocial variables, such as those assessed on
the Transplant Evaluation Rating Scale (TERS), and objective
outcomes, such as length of hospitalization and the number of
documented blood infections were evaluated. Based on the pa-
tient’s TERS score, each patient was stratified into one of
two groups (low/moderate risk (n5 134) vs. high risk (n5 21))
based on their predicted psychosocial risk for problems during
transplant. Although the two groups were similar in regards to
known pre-transplant prognostic factors such as age, perfor-
mance status, disease risk, and transplant type, there continues
to be a significant difference in the mean length of hospitaliza-
tion between patients who score low/moderate (10 days) and
those who scored high (16 days) on the TERS. Furthermore,
there was also a significant difference (p\.0001) in the total
number of blood infections per patient (48% of high risk pa-
tient had documented blood infections vs. 39% of low/moderate
risk patients had documented blood infections) based on their
TERS score. This data also revealed a significant difference in
the total number of blood infections over all between groups
(p\.0001). Although psychosocial factors appear to influence
a patient’s process during HSCT, it is not clear what particular
psychosocial factor most impacts these objective outcomes.
These findings suggest a strong correlation between pre-trans-
plant psychosocial risk factors and patient experiences in
HSCT.281
THE IMPACT OF DONOR TYPE AND ABO INCOMPATIBILITY ON TRANSFU-
SION REQUIREMENTS AFTER NONMYELOABLATIVE HEMATOPOIETIC
CELL TRANSPLANTATION (HCT)
Wang, Z.1, Sorror, M.L.1,3, Leisenring, W.1,2,4, Schoch, G.1,2,
Maloney, D.1,3, Sandmaier, B.M.1,3, Storb, R.1,3 1Fred Hutchinson Can-
cer Research Center, Seattle, WA; 2Fred Hutchinson Cancer Research
Center, Seattle, WA; 3School of Medicine, University of Washington, Se-
attle, WA; 4School of Public Health and Community Medicine, University
of Washington, Seattle, WA
We retrospectively analyzed transfusion requirements within the
first 100 days among 503 allogeneic HCT recipients with hemato-
logical malignancies given nonmyeloablative conditioning. We
compared transfusion needs among recipients given grafts 1)
